JAMA Oncology,
This Viewpoint advocates avoiding the use of first-line cetuximab- or panitumumab-containing regimens for patients with RAS wild…
This Viewpoint advocates avoiding the use of first-line cetuximab- or panitumumab-containing regimens for patients with RAS wild…
This viewpoint explains why one leading expert feels that the cost and toxicity of antibodies against epidermal growth factor…
This Viewpoint advocates avoiding the use of first-line cetuximab- or panitumumab-containing regimens for patients with RAS wild…
This Viewpoint advocates avoiding the use of first-line cetuximab- or panitumumab-containing regimens for patients with RAS wild…